FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2494135329> ?p ?o ?g. }

• W2494135329 endingPage "1758" @default.
• W2494135329 startingPage "1752" @default.
• W2494135329 abstract "Background Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Methods Retrospective review of OPTiM identified patients with cutaneous head and neck melanoma given talimogene laherparepvec (n = 61) or GM-CSF (n = 26). Outcomes were compared between talimogene laherparepvec and GM-CSF treated patients with cutaneous head and neck melanoma. Results DRR was higher for talimogene laherparepvec–treated patients than for GM-CSF treated patients (36.1% vs 3.8%; p = .001). A total of 29.5% of patients had a complete response with talimogene laherparepvec versus 0% with GM-CSF. Among talimogene laherparepvec–treated patients with a response, the probability of still being in response after 12 months was 73%. Median overall survival (OS) was 25.2 months for GM-CSF and had not been reached with talimogene laherparepvec. Conclusion Treatment with talimogene laherparepvec was associated with improved response and survival compared with GM-CSF in patients with cutaneous head and neck melanoma. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1752–1758, 2016" @default.
• W2494135329 created "2016-08-23" @default.
• W2494135329 creator A5009161783 @default.
• W2494135329 creator A5012965017 @default.
• W2494135329 creator A5030466764 @default.
• W2494135329 creator A5037617463 @default.
• W2494135329 creator A5042127830 @default.
• W2494135329 creator A5055054082 @default.
• W2494135329 creator A5061683749 @default.
• W2494135329 creator A5069118457 @default.
• W2494135329 creator A5072284989 @default.
• W2494135329 creator A5078503895 @default.
• W2494135329 creator A5089777560 @default.
• W2494135329 creator A5090739964 @default.
• W2494135329 date "2016-07-13" @default.
• W2494135329 modified "2023-10-13" @default.
• W2494135329 title "Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma" @default.
• W2494135329 cites W1965352121 @default.
• W2494135329 cites W1967262248 @default.
• W2494135329 cites W1974829403 @default.
• W2494135329 cites W1988379285 @default.
• W2494135329 cites W2003089135 @default.
• W2494135329 cites W2027916149 @default.
• W2494135329 cites W2063044121 @default.
• W2494135329 cites W2082150850 @default.
• W2494135329 cites W2097000480 @default.
• W2494135329 cites W2097995306 @default.
• W2494135329 cites W2109274792 @default.
• W2494135329 cites W2114694671 @default.
• W2494135329 cites W2118274970 @default.
• W2494135329 cites W2121545342 @default.
• W2494135329 cites W2125449782 @default.
• W2494135329 cites W2128542677 @default.
• W2494135329 cites W2147690537 @default.
• W2494135329 cites W2165320653 @default.
• W2494135329 cites W2166262263 @default.
• W2494135329 cites W2167925208 @default.
• W2494135329 cites W2211214375 @default.
• W2494135329 cites W81622822 @default.
• W2494135329 cites W84369551 @default.
• W2494135329 doi "https://doi.org/10.1002/hed.24522" @default.
• W2494135329 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5129499" @default.
• W2494135329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27407058" @default.
• W2494135329 hasPublicationYear "2016" @default.
• W2494135329 type Work @default.
• W2494135329 sameAs 2494135329 @default.
• W2494135329 citedByCount "48" @default.
• W2494135329 countsByYear W24941353292016 @default.
• W2494135329 countsByYear W24941353292017 @default.
• W2494135329 countsByYear W24941353292018 @default.
• W2494135329 countsByYear W24941353292019 @default.
• W2494135329 countsByYear W24941353292020 @default.
• W2494135329 countsByYear W24941353292021 @default.
• W2494135329 countsByYear W24941353292022 @default.
• W2494135329 countsByYear W24941353292023 @default.
• W2494135329 crossrefType "journal-article" @default.
• W2494135329 hasAuthorship W2494135329A5009161783 @default.
• W2494135329 hasAuthorship W2494135329A5012965017 @default.
• W2494135329 hasAuthorship W2494135329A5030466764 @default.
• W2494135329 hasAuthorship W2494135329A5037617463 @default.
• W2494135329 hasAuthorship W2494135329A5042127830 @default.
• W2494135329 hasAuthorship W2494135329A5055054082 @default.
• W2494135329 hasAuthorship W2494135329A5061683749 @default.
• W2494135329 hasAuthorship W2494135329A5069118457 @default.
• W2494135329 hasAuthorship W2494135329A5072284989 @default.
• W2494135329 hasAuthorship W2494135329A5078503895 @default.
• W2494135329 hasAuthorship W2494135329A5089777560 @default.
• W2494135329 hasAuthorship W2494135329A5090739964 @default.
• W2494135329 hasBestOaLocation W24941353291 @default.
• W2494135329 hasConcept C121608353 @default.
• W2494135329 hasConcept C126322002 @default.
• W2494135329 hasConcept C141071460 @default.
• W2494135329 hasConcept C143998085 @default.
• W2494135329 hasConcept C2777658100 @default.
• W2494135329 hasConcept C3018411727 @default.
• W2494135329 hasConcept C502942594 @default.
• W2494135329 hasConcept C71924100 @default.
• W2494135329 hasConcept C82210918 @default.
• W2494135329 hasConceptScore W2494135329C121608353 @default.
• W2494135329 hasConceptScore W2494135329C126322002 @default.
• W2494135329 hasConceptScore W2494135329C141071460 @default.
• W2494135329 hasConceptScore W2494135329C143998085 @default.
• W2494135329 hasConceptScore W2494135329C2777658100 @default.
• W2494135329 hasConceptScore W2494135329C3018411727 @default.
• W2494135329 hasConceptScore W2494135329C502942594 @default.
• W2494135329 hasConceptScore W2494135329C71924100 @default.
• W2494135329 hasConceptScore W2494135329C82210918 @default.
• W2494135329 hasFunder F4320307105 @default.
• W2494135329 hasIssue "12" @default.
• W2494135329 hasLocation W24941353291 @default.
• W2494135329 hasLocation W24941353292 @default.
• W2494135329 hasLocation W24941353293 @default.
• W2494135329 hasLocation W24941353294 @default.
• W2494135329 hasLocation W24941353295 @default.
• W2494135329 hasOpenAccess W2494135329 @default.
• W2494135329 hasPrimaryLocation W24941353291 @default.
• W2494135329 hasRelatedWork W1996381657 @default.
• W2494135329 hasRelatedWork W2002161240 @default.

• next